Introduction
Adult T-cell leukemia (ATL) was identified as a distinct clinical entity in 1977 based on its unique distribution among patients, clinical and immunological features Uchiyama et al., 1977) . Thereafter, its causative agent, human Tcell leukemia virus type I (HTLV-I) was identified in a cell line derived from a patient with cutaneous T-cell lymphoma (Poiesz et al., 1980) . In addition, the close linkage between ATL and HTLV-I has been demonstrated by the presence of antibody against viral antigens in the sera of patients with ATL (Hinuma et al., 1981) . Therefore, HTLV-I was the first retrovirus shown to be associated with the human disease. The discovery of ATL and HTLV-I had far-reaching effects not only in medicine and virology, but also in oncology and biology.
The presence of HTLV-I provirus enables us to analyse each step of leukemogenesis from infection to the highly aggressive acute or lymphoma types of ATL. Therefore, ATL is a good model to clarify the oncogenesis of lymphoid cells.
Molecular biology of HTLV-I-encoded proteins
HTLV-I belongs to the Delta-type retroviruses, which also include the bovine leukemia virus (BLV), the human T-cell leukemia virus type II (HTLV-II), and the simian T-cell leukemia virus (STLV). BLV and STLV have also been associated with neoplastic diseases as well as HTLV-I. Like other retroviruses, the HTLV-I proviral genome has gag, pol and env genes, flanked by long terminal repeat (LTR) sequences at both ends (Seiki et al., 1983) . A unique structure was found between env and the 3 0 -LTR, denoted the pX region, which encodes the regulatory proteins: p40 tax (Tax), p27 rex (Rex), p12, p30 and p21 ( Figure 1 ). Among them, Tax protein is thought to play a central role in the leukemogenesis of ATL, because of its pleiotropic actions ( Figure 2 ) (Franchini, 1995; Yoshida, 2001) . Tax potently increases the expression of viral genes through the viral LTR, and also stimulates the transcription of cellular genes through cellular signaling pathways of NF-kB, CREB, SRF and AP-1. Tax does not bind to promoter or enhancer sequences by itself, but it interacts with cellular proteins that are transcriptional factors or modulators of cellular functions.
Transcriptional activation
Tax can activate the NF-kB pathway by interacting with IKKg. IKKa, b and g form 700 kDa complex, in which IKKg functionally adapts Tax into this large complex (Jin et al., 1999; Jeang, 2001) . The activated complex phosphorylates IkB, which detaches NF-kB, resulting in the activation of NF-kB. Activation of NF-kB induces transcription of various cytokines and their receptor genes as well as numerous genes associated with apoptosis and cell cycle. For example, Tax can activate the transcription of interleukin (IL)-2Ra and IL-2 genes through the NF-kB pathway (Ballard et al., 1988; Wano et al., 1988) . In addition, transcription of IL-6 (Muraoka et al., 1993) , IL-15 (Azimi et al., 1998) and GM-CSF (Himes et al., 1993) genes can be activated by Tax protein via NF-kB. Such activation of genes associated with cell proliferation seems to be involved in the growth of HTLV-I-infected cells both in vitro and in vivo. Tax can also induce expression of Bcl-X L via the activation of NFkB, which renders ATL cells apoptosis resistant (Tsukahara et al., 1999) . As in HTLV-I-transformed cell lines, increased expression of Bcl-X L was observed in fresh ATL cells. This finding may account for the resistance of ATL cells to chemotherapy (Nicot et al., 2000) .
For the activation of the viral LTR, Tax requires at least two 21-bp enhancers containing an imperfect cAMP-responsive element, to which the cyclicAMP response element binding protein (CREB) binds (Zhao and Giam, 1992) . Tax can bind to both CREB and CREB binding protein (CBP), the latter of which is a transcriptional coactivator (Kwok et al., 1996) . Under physiological conditions, only phosphorylated CREB induced by stimulation can bind to CBP. Tax shunts this pathway, resulting in stimulation-independent activa- 
Transcriptional repression
Conversely, Tax can trans-repress the transcription of certain genes, such as DNA polymerase b , lck (Lemasson et al., 1997) , p18 and p53 (Suzuki et al., 1999) genes. For trans-repression of p18 gene transcription, the E-box, which binds to transcriptional factor, E47, is critical. Tax protein itself could not bind to E-box or E47, but interfered with binding of E47 to the transcriptional coactivator, p300, resulting in the repression of transcription (Suzuki et al., 1999) . p53-dependent transcription is also repressed by Tax protein.
Similar to trans-repression of p18, Tax does not bind to p53 or p53-binding site, but rather it inhibits the recruitment of CBP to p53 on the p53-binding sites (Suzuki et al., 1999; Ariumi et al., 2000) . This mechanism of trans-repression contrasts with that of trans-activation of CREB pathway by Tax protein.
Although both mechanisms depend on binding of Tax protein to the transcriptional activator, CBP/p300, their effect on transcription is quite different (Yoshida, 2001 ).
Functional inhibition
Apart from transcriptional regulation, Tax can influence the function of cellular factors. Tax protein can interact with a negative inhibitor of cyclin-dependent kinase (CDK) 4, p16
INK4a
, via its ankyrin motif, and impair its function (Suzuki et al., 1996) . Since p16
INK4a is an inhibitor of CDK4, its functional inactivation leads to the activation of CDK4/6, phosphorylation of Rb, and finally G1/S transition.
Transforming growth factor b (TGF-b) is an inhibitory cytokine that plays important roles in development, the immune system and oncogenesis. Since TGF-b generally suppresses the growth of tumor cells, most of the tumor cells acquire the escape mechanisms to inhibit signaling from TGF-b, which include mutation of its receptor and mutation of Smad molecules that transduce the signal from receptor. Tax is also reported to inhibit the signal of TGF-b binding to Smad2, 3 and 4 or CBP/p300 (Mori et al., 2001; Lee et al., 2002) . Inhibition of TGF-b signaling enables HTLV-I-infected cells to escape TGF-b-mediated growth inhibition.
ATL cells are well known to show remarkable chromosomal abnormalities, which are thought to reflect chromosomal instability. Tax has been reported to interact with the checkpoint protein, MAD1, which forms a complex with MAD2 and controls the mitotic checkpoint. The functional hindrance of MAD1 by Tax protein causes chromosomal instability, suggesting the involvement of this mechanism in oncogenesis (Jin et al., 1998) .
Molecular biology of p12
Open reading frame (ORF) 1 of pX region encodes p12 (Figure 1) , which is present in the endoplasmic reticulum and the Golgi apparatus (Ding et al., 2001) . p12 has been shown to play an important role in the establishment of HTLV-I infection and optimal viral infectivity in vivo (Collins et al., 1998) and quiescent primary lymphocytes (Albrecht et al., 2000) . Several mechanisms of p12 have been suggested to facilitate infectivity; p12 interacts with calreticulin and calnexin, and increases cytoplasmic calcium, leading to NFAT activation in T-lymphocytes (Ding et al., 2002) . This action of p12 facilitates host cell activation and establishment of persistent infection. Another mechanism is that p12 binds to the cytoplasmic domain of IL-2R b chain, which increases the DNA binding and transcription activities of signal transducers and activators of transcription (STAT) 5 (Nicot et al., 2001) . Although the expression of p12 protein in vivo has remained obscure, cytotoxic T lymphocytes (CTLs) against p12 has been demonstrated in the individuals infected with HTLV-I, indicating that p12 protein was expressed in vivo (Pique et al., 2000) .
HTLV-I therefore has redundant strategies to increase infected cells through its encoded proteins, Tax and p12, which promote cell proliferation, inhibit apoptosis and increase genetic and chromosomal instability. With these strategies, HTLV-I increases its copies in vivo by increasing infected cell numbers, and causes ATL as a consequence of the strategies.
Immunological aspects of HTLV-I infection

Immune response against Tax
Whereas Tax evokes the clonal proliferation of HTLV-Iinfected cells, it has been shown to be a major target of CTLs in vivo (Jacobson et al., 1990; Kannagi et al., 1991) . Therefore, Tax-expressing cells are considered to be eliminated in vivo. Indeed, depletion of CD8-positive T lymphocytes from the peripheral blood mononuclear cells of HTLV-I-infected individuals in vitro promoted Tax expression in the CD4-positive subpopulation, indicating that CD8-positive CTLs suppressed Tax expression in vivo (Hanon et al., 2000a) . Thus, the survival of HTLV-I-infected cells depends on the balance of proliferative actions of Tax and the host immune system. The enigma about CTLs against Tax is that in patients with HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP), a high frequency of CTLs against Tax was observed in spite of a high provirus load (increased number of HTLV-Iinfected cells). Analysis of CTLs with fluorescent-labeled tetrameric complexes of HLA-A*02/b2 microglobulin/ Tax 11-19 peptide showed that CTL response is effective in asymptomatic carriers; however, it is ineffective (weak CTL response) in patients with HAM/TSP (Wodarz et al., 2001) . These findings suggest that in asymptomatic carriers, CTLs against HTLV-I can control the growth of cells carrying the HTLV-I provirus, resulting in the prevention of development of ATL.
Immunodeficiency in ATL patients and HTLV-I carriers
ATL is a highly aggressive neoplastic disease; the mean survival time of patients with acute ATL is less than 1 year regardless of intensive chemotherapy. The major obstacles in the treatment of patients with ATL include drug resistance and development of opportunistic infections, caused by various organisms such as Pneumocystis carinii, cytomegalovirus, Strongyloidiasis and a variety of fungi, indicating that cell-mediated immunity is severely impaired in these patients (Shimoyama, 1994; Matsuoka and Takatsuki, 2002) . Although the frequency of opportunistic infections is much higher in patients with ATL than in those with other hematological malignancies, the underlying mechanism(s) of this phenomenon remained obscure. Opportunistic malignancies, Kaposi's sarcoma (Greenberg et al., 1990) and Epstein-Barr virus (EBV)-associated lymphoma (Tobinai et al., 1991) have also been reported in patients with ATL, indicating a state of immunodeficiency in these patients, which is similar to that observed in acquired immunodeficiency syndrome (AIDS). Impaired cell-mediated immunity, such as suppressed Tcell response to EBV (Katsuki et al., 1987) , and seronegativity against purified protein derivative (PPD) (Welles et al., 1994) , has been reported in HTLV-I carriers, also indicating relation to immunodeficiency.
Several mechanisms were reported to account for this immunodeficient state of HTLV-I-infected individuals. One is that HTLV-I infects CD8-positive T lymphocytes, which impairs the function of CD8-positive T lymphocytes (Nagai et al., 2001) . Indeed, the immune response against Tax, via HTLV-I-infected CD8-positive T cells, renders these cells susceptible to fratricide mediated by autologous HTLV-I-specific CD8-positive T lymphocytes. Fratricide among virus-specific CTLs could impair the immune control of HTLV-I (Hanon et al., 2000b) . Another mechanism of immunodeficiency is based on the observation that the number of naive T cells decreased in individuals infected with HTLV-I. Naive T cells were identified by three-color fluorescence with CD62L and CD45RA coexpression either with CD4-or CD8-positive T cells. The number of naive T lymphocytes was markedly suppressed in patients with ATL, particularly in those with acute form, compared with uninfected control individuals. The number of naive T cells was low in HTLV-I-infected individuals under 50 years of age compared with uninfected individuals, whereas the number of memory T lymphocytes was greater in HTLV-I-infected individuals. T-cell receptor rearrangement excision circles (TREC), which are generated by DNA recombination during early T lymphopoiesis, were quantified to evaluate thymic function in HTLV-I-infected individuals. TREC levels were lower in HTLV-I-infected individuals than in uninfected individuals. The suppressed number of naive T lymphocytes was because of suppressed production of T lymphocytes in the thymus, which might account for the immunodeficiency observed in HTLV-I-infected individuals (Yasunaga et al., 2001 ).
Immunodeficiency and development of ATL
Such immunodeficiency might be associated with leukemogeneisis of ATL by allowing proliferation of HTLV-I-infected cells. A prospective study of HTLV-Iinfected individuals identified carriers who later developed ATL, showed that the anti-Tax level was low in all ATL cases for up to 10 years preceding their diagnosis, independent of the level of anti-HTLV-I titer. This finding indicates that HTLV-I carriers with a higher anti-HTLV-I titer and a lower anti-Tax reactivity may be at greatest risk of ATL (Hisada et al., 1998) . The levels of anti-HTLV-I antibody and soluble IL-2 receptor (sIL-2R) have been shown to be correlated with HTLV-I provirus load (Etoh et al., 1999) , and high antibody titers, and high sIL-2R were risk factors to develop ATL among carriers (Arisawa et al., 2002) . Taken together, these findings suggest that a higher proliferation of HTLV-I-infected cells, and a low response against Tax might be associated with the onset of ATL. Given this finding, potentiation of CTLs against Tax by a vaccine strategy might be useful in preventing the onset of ATL (Hanabuchi et al., 2001) .
EBV-associated lymphomas frequently develop in individuals with immunodeficient state associated with transplantaion or AIDS. Does such an immunodeficeint state, which abrogates the immune function suppressing HTLV-I-infected cells, affect the onset of ATL? Among 24 patients with post-transplantation lymphoproliferative disorders (PT-LPD) after renal transplantation in Japan, five cases of ATL were reported (Hoshida et al., 2001) . Considering that most of PT-LPD was B-cell origin in the Western countries, this frequency of ATL was quite high. Although HTLV-I was thought to be transmitted via blood transfusion during hemodialysis, the immunodeficient state might promote the onset of ATL.
Epidemiology and natural course of HTLV-I infection leading to onset of ATL Throughout the world, about 20 million people are estimated to be infected with HTLV-I. HTLV-I is endemic in southwest Japan, the Caribbean islands, countries surrounding the Caribbean basin and parts of Central Africa. In addition, epidemiological studies of HTLV-I revealed high seroprevalence rates in Melanesia, Papua New Guinea, the Solomon islands and among Australian aborigines (Blattner and Gallo, 1994) . In Japan, approximately 1.2 million individuals were estimated to be infected by HTLV-I, and more than 800 cases of ATL are diagnosed each year (Tajima et al., 1994) . The cumulative risk of ATL among HTLV-I carriers in Japan was estimated at about 6.6% for men and 2.1% for women, indicating that most of the HTLV-I carriers are asymptomatic throughout their whole life (Arisawa et al., 2000) .
Transmission of HTLV-I
HTLV-I is transmitted by the three routes: (1) vertical (mother-to-infant: in the breast milk or transplacental), (2) horizontal (sexual) and (3) parenteral (blood transfusion or intravenous drug use) routes. Via any of the routes, infected cells are essential for transmission of HTLV-I, which has been shown by the absence of seroconvertors among recipients of fresh frozen plasma transfusions (Okochi et al., 1984) . Similarly, infection with HTLV-I could be established by coculture of infected cells in vitro. Thus, HTLV-I requires infected living cells for transmission. HTLV-I therefore has strategies to increase its infected cell numbers in vivo described later.
HTLV-I can infect many types of cells including B lymphocytes, dendritic cells, fibroblast, rat cell, mouse cells, indicating that its receptor is ubiquitously expressed on cell surfaces. However, HTLV-I provirus was predominantly found in the CD4-positive T lymphocytes (Yasunaga et al., 2001) . This suggested that HTLV-I could increase the number of infected CD4 þ T lymphocytes in vivo after infection, coinciding with the finding that HTLV-I could transform CD4-positive T lymphocytes in vitro. Even a retrovirus vector expressing only Tax could transform T lymphocytes in vitro (Akagi et al., 1995) . Taken together, these findings suggest that Tax promotes the proliferation, and inhibits apoptosis of HTLV-I-infected CD4-positive T lymphocytes in vivo.
HTLV-I provirus load
HTLV-I provirus load, which is correlated with the number of HTLV-I-infected cells, varied by more than 100-fold among HTLV-I carriers. Whether the provirus load is constant or variable over time in individuals is an important issue. To address this question, sequential DNA samples from peripheral blood mononuclear cells of HTLV-I carriers who were followed in a Miyazaki cohort study were analysed; provirus loads fluctuated only two-to fourfold in most carriers, showing that provirus loads were relatively constant over time for up to 7 years in individual carriers (Etoh et al., 1999) .
What determines the provirus load in carriers? As shown in the previous studies, age and sex did not influence provirus load (Etoh et al., 1999) . A quantitative study of HTLV-I provirus load in seroconverters revealed that the same virus sequences were identified in the married couples (infected persons transmitted virus to partners); however, their provirus load were quite different, suggesting that provirus load was determined not by HTLV-I itself, but rather by host factors (Iga et al., 2002) . It is assumed that immune responses, especially CTLs against HTLV-I, control the number of HTLV-I-infected cells. As described above, CTLs in asymptomatic carriers control the proliferation of HTLV-I-infected cells, and suppress the development of ATL (Wodarz et al., 2001) . Another explanation for differences in provirus load is that genetic factors, other than MHC, influence the provirus load. Polymorphism of tumor necrosis factor a (TNF-a) has been shown to be associated with ATL in comparison with asymptomatic carriers, suggesting that genetic polymorphism that increases the production of TNF-a is associated with susceptibility to ATL (Tsukasaki et al., 2001) . Such genetic analysis utilizing rapidly accumulating knowledge and developing technology will clarify the genetic basis of familial clustering of ATL patients.
Clonal expansion of HTLV-I-infected cells
In HTLV-I carriers, HTLV-I provirus is randomly integrated in the host genome. In other words, the integration site is specific to each HTLV-I-infected cell (Seiki et al., 1984) . Part of the LTR and flanking genomic DNAs were amplified by inverse PCR, with each detected band representing a clonal proliferation of HTLV-I-infected cells. Using this assay to analyse clonal proliferation of HTLV-I-infected cells in HTLV-I carriers, some clones were shown to persist over 7 years in the same individuals (Cavrois et al., 1998; Etoh et al., 1997) . These persistent clones were CD4-positive lymphocytes, which is consistent with the finding that HTLV-I predominantly immortalizes CD4-positive T lymphocytes in vitro.
The HTLV-I provirus is genetically very stable, especially when compared with the other major human retrovirus, human immunodeficiency virus (HIV). It has been postulated that increased HTLV-I load is achieved not by replication of virus, but by clonal proliferation of infected cells. Since reverse transcriptase is an errorprone DNA polymerase, higher replication rate generates the vast diversity in the virus genome. In HIV, a higher rate of mutation generated in the viral replication results in the acquisition of drug resistance, and escapes from the host immune system. On the other hand, HTLV-I increased its copies by proliferation of HTLV-I-infected cells. In such situation, HTLV-I provirus in the host cells is replicated by cellular DNA polymerase with proofreading activity. Therefore, HTLV-I provirus is genetically stable in a striking contrast to HIV-I.
Tax in ATL cells
A long latent period of about 60 years precedes the onset of ATL, suggesting the multistep mechanism of leukemogenesis (Okamoto et al., 1989) (Figure 3 ). Most importantly, ATL cells frequently lost the expression of Tax by several mechanisms. The 5 0 -LTR is a viral promoter for transcription of viral genes, including the tax gene. The 5 0 -LTR was reported to be lost in 39% of the cases examined (21/54 cases), indicating that ATL cells with such a provirus could no longer produce Tax (Tamiya et al., 1996) . The second mechanism is the nonsense or missense mutation of the tax gene in fresh ATL cells. Interestingly, in some cases, ATL cells had mutation in class I MHC recognition site of Tax protein, resulting in escape from immune recognition (Furukawa et al., 2001) . The third mechanism is epigenetic change of the 5 0 -LTR: the 5 0 -LTR was selectively methylated, which silenced the transcription of viral genes (Koiwa et al., 2002) . With these mechanisms, ATL cells lost Tax expression, and could escape from the host immune surveillance system. Tax promotes the proliferation of HTLV-I-infected cells by its pleiotropic actions; however, it is the major target of CTL. Thus, the presence of Tax in HTLV-I-infected cells provides advantages and disadvantages for the survival of HTLV-I-infected cells.
It is speculated that Tax plays an important role in persistent proliferation of HTLV-I-infected cells during the carrier state, and then genetic and epigenetic changes accumulate in the host genome mediated by mutator phenotype of Tax , which finally leads to Tax-independent proliferation and escape from the host immune system by inactivation of the tax gene.
Alternations in the host genome of ATL cells
Various mutations of oncogenesis and tumor-suppressor genes have been demonstrated in cancers and it has been established that multiple changes are necessary for the appearance of malignant disease. In ATL cells, previous studies have demonstrated mutations of p53 gene in about 30% of patients (Cesarman et al., 1992; Sakashita et al., 1992) , while we observed such mutations in 11% (Takeda et al., unpublished data). p53 mutations were detected in more aggressive disease state. Moreover, deletion or mutation of the p16 INK4A gene was also reported in ATL (Hatta et al., 1995) . Again, those abnormalities were observed in acute or lymphoma-type ATL, suggesting that somatic DNA changes in p53 or p16
INK4A genes are associated with the progression of ATL. Mutations of Fas gene are also reported in patients with ATL cells (Tamiya et al., 1998; Maeda et al., 1999) . However, such genetic changes were not frequently detected. In this regard, epigenetic change of
p16
INK4A gene was more frequent in ATL cells, and accumulated according to the disease progression (Nosaka et al., 2000) . This finding suggests that epigenetic change, including DNA methylation, plays an important role in the leukemogenesis of ATL.
Molecular pathogenesis of ATL
In the immune system, CD4-positive T lymphocytes play a central role by controlling the immune cells, such as B lymphocytes, dendritic cells CTLs, and their responses. Helper T lymphocytes secrete various cytokines to control the immune response and express adhesion molecule or chemokine receptors that influence their migration, and costimulatory molecules that mediate differentiation and activation of various cells. Since ATL cells are derived from helper T lymphocytes, they exhibit various phenotypes similar to the original cells.
Cytokines
ATL cells has been shown to produce various cytokines, including IL-1 (Wano et al., 1987) , IL-6 (Villiger et al., 1991) , TGF-b (Niitsu et al., 1988) , IL-5, M-CSF, GM-CSF and parathyroid hormonerelated protein (PTH-rP) (Watanabe et al., 1990) . Such cytokines can modify the clinical manifestations of 
Chemokine receptor
Chemokines and their receptors have been implicated in the migration and tissue localization of lymphocytes. ATL cells are well known to infiltrate into various organs or tissues, frequently invading skin or lymphoid tissues. The differential expression of chemokine receptors might determine the migration of ATL cells. Analysis of chemokine receptor expression revealed that CCR4 was frequently expressed on HTLV-I-transformed cell lines and fresh ATL cells (Yoshie et al., 2002) . CCR4-positive T lymphocytes contain skin-seeking memory T cells, suggesting that expression of CCR4 accounts for frequent infiltration of ATL cells into skin. On the other hand, expression of CCR7 was reported to be associated with the involvement of lymphoid tissues, and lymph node enlargement (Hasegawa et al., 2000) .
A subtraction strategy between ATL cell lines and activated T cells identified I-309 as a secreted chemokine from ATL cells, and I-309 expression was remarkably enhanced in ATL cell lines (Ruckes et al., 2001) . I-309 showed antiapoptotic effect via its receptor CCR8, invoking that an autocrine mechanism via I-309/CCR8 allowed ATL cells to survive in vivo.
RANK ligand
The high frequency of hypercalcemia is the most striking feature of ATL; about 70% of ATL patients have high serum Ca 2 þ levels during the clinical course of the disease, particularly during the aggressive stage of ATL (Kiyokawa et al., 1987) . Such a frequency is the highest among hematological malignancies, and hypercalcemia is more severe in patients with ATL than those with other hematological malignancies (Roodman, 1997) . In hypercalcemic patients, serum Ca 2 þ levels are often 420 mg/ml, and accordingly, most patients are in a state of coma. Several pathological studies of ATL patients with hypercalcemia have indicated that high serum Ca 2 þ levels are because of an increased number of osteoclasts (OCL) and accelerated bone resorption (Gibbs et al., 1987; Kiyokawa et al., 1987) . Several cytokines, such as IL-1 (Wano et al., 1987) , TGF-b (Niitsu et al., 1988; Kim et al., 1990) , and PTH-rP (Watanabe et al., 1990) have been implicated in ATL-associated hypercalcemia. Among these factors, PTH-rP is considered to play an important role by stimulating OCLs, resulting in increased bone resorption. Immunodeficient mice implanted with leukemic cells from patients with ATL exhibited hypercalcemia and overexpressed PTH-rP (Takaori-Kondo et al., 1998). However, PTH-rP cannot directly induce the differentiation of hematopoietic precursor cell (HPC) to OCL (Matsuzaki et al., 1999) . Furthermore, high serum levels of PTH-rP are not always associated with hypercalcemia in patients with ATL, suggesting that another factor is involved in the pathogenesis of hypercalcemia (Yamaguchi et al., 1994) .
Bone is constitutively remodeled by osteoblasts (matrix synthesis) and OCL (bone resorption). OCL are derived from HPCs, and belong to the monocyte macrophage lineage. During differentiation of OCL, precursor cells sequentially express c-Fms (receptor of M-CSF) followed by receptor activator nuclear factor kB (RANK) . M-CSF and RANK ligand (RANKL) have been shown to be critical factors for the differentiation of OCL, which are physiologically produced by stromal cells and osteoblasts (Lacey et al., 1998) . Kong et al. (1999) identified abnormal expression of RANKL on activated T lymphocytes and postulated that this gene is associated with bone loss and joint destruction in inflammatory arthritis. Among the genes associated with hypercalcemia, increased expression of the RANKL gene correlated with hypercalcemia in ATL. ATL cells from patients with hypercalcemia, which highly expressed the transcripts of the RANKL gene, induced the differentiation of HPCs into OCL in vitro in the presence of M-CSF. In contrast, ATL cells from patients without hypercalcemia did not induce such differentiation, suggesting that the induction of differentiation correlated with the expression of the RANKL gene in ATL cells. Cell differentiation was suppressed by osteoprotegerin/Fc (OPG/Fc), an inhibitor of RANKL, indicating that such differentiation occurred via the RANK-RANKL signal. In addition, direct contact between ATL cells and HPC was essential for the differentiation, suggesting that membrane-bound RANKL, but not the soluble form, played a role in this process (Nosaka et al., 2002) . These results suggested that ATL cells induce the differentiation of HPC to OCL via RANKL expressed on their surface, in cooperation with M-CSF, and ultimately cause hypercalcemia.
OX40
OX40/OX40L, members of TNFR/TNF superfamily, plays an important role in the activation of T cell that transduce the costimulatory signal. The OX40 signal suppressed apoptosis of T cell by promoting expression of Bcl-X L and Bcl-2, resulting in the survival of CD4-positive T cells (Rogers et al., 2001) . OX40 is expressed on HTLV-I-infected T cells, and was also isolated as a molecule that served in adhesion to endothelial cells (Imura et al., 1996) , suggesting that OX40/OX40 system is implicated in the survival and tissue infiltration of ATL cells.
Thus, ATL cells express various molecules that can modify their phenotypic properties, thereby modifying the clinical disease manifestation, and facilitating the survival of ATL cells.
Treatment of ATL
Regardless of the extensive progress in virology, immunology and molecular biology of ATL and HTLV-I, the prognosis of patients with ATL remains poor. ATL is generally treated with aggressive combination chemotherapy, but long-term success has been less than 10%. The acute form, with hypercalcemia, high LDH levels and an elevated white blood cell count shows a particularly poor prognosis. Although G-CSF supported combination chemotherapy with eight drugs improved the survival (mean survival time 13 months) (Yamada et al., 2001) , the prognosis of aggressive ATL remains poor with deaths usually being the result of severe infection or hypercalcemia, often associated with drug resistance.
After a successful allogeneic bone marrow transplantation (alloBMT) for a patient with ATL was reported (Borg et al., 1996) , more patients with ATL were treated with alloBMT . This study demonstrated the low risk of relapse in cases with graftversus-host disease, suggesting that graft-versus-leukemia was effective against ATL cells. CTLs attack ATL cells via Fas ligand, perform or granzyme. These results are consistent with the finding that ATL cells are highly susceptible to the signal via Fas antigen. Thus, the signal through Fas antigen might be a good target in therapy against ATL.
Tax is well known to activate the NF-kB pathway, which play a central role in promoting cell proliferation, and inhibiting apoptosis as described above. ATL cells that do not express Tax also have an activated NF-kB pathway, although the mechanism of activation remains unknown (Mori et al., 1999) . From this point of view, suppression of NF-kB pathway might be a good therapeutic target against ATL. Indeed, inhibition of the NF-kB pathway by Bay 11-7082, an inhibitor of NFkB, induced apoptosis of HTLV-I-transformed cell lines and ATL cells, suggesting that inhibitors against NF-kB pathway are effective against ATL cells in vivo (Mori et al., 2002) .
Conclusion
After establishment of ATL as a distinct clinical entity, and identification of HTLV-I as a causative agent of this disease, extensive studies on ATL and HTLV-I in the field of virology, immunology and molecular biology have clarified many aspects of this virus and diseases (ATL and HAM/TSP). However, the precise mechanism of leukemogenesis remains unsolved, and most importantly, successful therapy for ATL has not been established. Future research will be directed at clarifying the mechanism of leukemogenesis, including alterations of the host genome, and based on this knowledge, new therapeutic strategies against this highly malignant disease should be formulated.
